Anti-Inflammatory Peptides Market Size Worth US$ 139.4 billion by 2030 – Growth Plus Reports

Newark, New Castle, USA, March 03, 2023 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global anti-inflammatory peptides market is expected to clock US$ 139.4 billion by 2030 and to grow at a CAGR of 4% during the forecast period. Owing to the increased development of innovative therapies globally. This exclusive information is published by Growth Plus Reports in its report titled “Anti-Inflammatory Peptides Market – Global Outlook & Forecast 2022-2030”

Get a Free Sample Research Report:

Growth Drivers

The expansion of the global anti-inflammatory peptides market is anticipated to be driven by the growing elderly population base, which weakens natural immunity in the direction of the pro-inflammatory status of the human body. During the projected period, the market for anti-inflammatory peptides is anticipated to grow as more people worldwide adopt unhealthy lifestyles and obesity rates rise. In the upcoming years, the rise of the worldwide anti-inflammatory peptides market is projected to be driven by the presence of sophisticated and well-established healthcare infrastructures in developed areas. During the projection period, there are expected to be abundant prospects for market expansion due to ongoing research to discover new and efficient anti-inflammatory peptides. The rising prevalence of inflammatory diseases such as psoriasis, rheumatoid arthritis, ulcerative colitis, inflammatory bowel diseases, and others is one of the major factors driving the growth of the anti-inflammatory peptides market. According to the Centers for Disease Control and Prevention, 78 million Americans will have arthritis that a doctor has officially diagnosed by 2040. During the anticipated time term, this is expected to drive the market. The industry is also predicted to profit from the increased incidence of atopic dermatitis and the growing usage of corticosteroids in treating asthma and COPD.

The global anti-inflammatory peptides market has been analyzed from three perspectives: Application, Distribution Channel, and Region.

Excerpts from ‘By Application Segmentation’

Based on application, the global anti-inflammatory peptides market has been subdivided into:

  • Gastrointestinal Diseases
  • Neurological Diseases
  • Cardiovascular Diseases
  • Dermatological Diseases
  • Renal Diseases
  • Ophthalmological Diseases
  • Transplantation
  • Respiratory Diseases & Pulmonary Disorders
  • Rheumatological & Autoimmune Diseases

In the pharmaceutical business, using peptide-based medicines to treat cancer is becoming more important. The collateral harm has sparked the need for more effective cancer treatments that chemotherapy, radiation, and other cancer treatments inflict on healthy cells. As a result, the global market for anti-inflammatory peptides is predicted to greatly increase cancer incidence. The cardiovascular disorders segment held the largest market share in the global anti-inflammatory peptides market as a result of the rising prevalence of cardiovascular issues among the population. The dominance of this segment was also aided by the growing aging population and rising rates of obesity brought on by an unhealthy lifestyle. Canakinumab and colchicine are two more anti-inflammatory drugs that have lately shown an ability to reduce the incidence of cardiovascular events in secondary prevention.

Excerpts from ‘By Distribution Channel Segmentation’

Based on the distribution channel, the global anti-inflammatory peptides market has been subdivided into:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

The retail pharmacy segment is expected to grow significantly in the forecast period. Pharmaceuticals, dietary supplements, and innovative food supplements use bioactive peptides. This factor is thus leading to the growth of this segment.

Excerpts from ‘By Region Segmentation’

Based on region, the global anti-inflammatory peptides market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

North America is anticipated to dominate the global market for anti-inflammatory peptides because of the region’s extensive research and development efforts, accessibility to technologically cutting-edge systems, and growing patient awareness. One of the main reasons North America is leading the global market is, the high prevalence of psoriasis and multiple sclerosis in the region. Based on the 2020 US census data, an estimated 7.55 million US adults suffers from psoriasis. Latin America is anticipated to grow at a healthy rate as a result of a rise in both private and public associations, which has increased finance, as a result, increased demand for anti-inflammatory peptides. Also, the primary factors driving the anti-inflammatory therapeutic market in Asia-Pacific are an exponential rise in population, rising healthcare spending, and an increase in the prevalence of chronic, lifestyle-related, respiratory, and infectious diseases. Branded generics are increasing their market share thanks to more effective treatments, aggressive marketing strategies, and promotions.

Request for Customization –

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global anti-inflammatory peptides market are:

  • Araim Pharmaceuticals, Inc.
  • Novartis AG
  • Abbvie Corporation
  • Pfizer Inc.
  • Eli Lilly and Company
  • Mylan Pharmaceuticals
  • F4 Pharma
  • Digna Biotech
  • Rogne Bioscience
  • Meridian Biosciences

Anti-Inflammatory Peptides Market Scope

Report Attribute Details
Market size value in 2021 US$ 98 billion
Revenue forecast in 2030 US$ 139.4 billion
Growth Rate CAGR of 4% from 2022 to 2030
Base year for estimation 2021
Forecast period 2022-2030
Historical Year 2020
Segments covered Application, Distribution Channel, and Region.
Regional scope North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Gastrointestinal Diseases
    2. Neurological Diseases
    3. Cardiovascular Diseases
    4. Dermatological Diseases
    5. Renal Diseases
    6. Ophthalmological Diseases
    7. Transplantation
    8. Respiratory Diseases & Pulmonary
    9. Rheumatological & Autoimmune Diseases

TOC Continued.

Inquiry Before Buying:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse related reports:

Fundus Cameras Market by Product Type (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras), Modality (Handheld, Tabletop), End User (Hospitals, Ophthalmology Clinics) – Global Outlook & Forecast 2023-2031

Synovial Sarcoma Therapeutics Market by Therapy (Anti-Angiogenesis Drugs and Chemotherapy), End-user (Hospitals, Speciality Clinics) – Global Outlook and Forecast 2023-2031

Adrenocorticotropic Hormone Market by Source (Natural, Synthetic), Application (Neurology, Rheumatology), End-user (Hospitals and Clinics, Home Care) – Global Outlook & Forecast 2023-2031

Large Granular Lymphocytic Leukemia Market by Drug Class (Antineoplastic, Immunosuppressants, Alkylating Agents) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Breath Analysers Market by Technology (Fuel Cell Technology, Semiconductor Sensor), by Application (Drug Abuse Detection, Alcohol Detection) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:  

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.